One Pivotal Trial for FDA Approval? Success Depends on Trial Design

The U.S. Food and Drug Administration (FDA) has quietly announced one of the most significant changes to clinical development policy.

Rather than expecting two clinical trials as the default standard for marketing approval, the FDA now intends to accept one adequate and well-controlled pivotal trial, supported by confirmatory evidence, for approval in many situations.

Image

From Two Trials to One: Why the FDA Is Changing Course

The proposal announced in a research paper by an FDA Sounding Board does not lower the evidentiary bar for clinical study approval submissions.

Instead, it shifts the focus from the number of studies to the quality, credibility, and totality of evidence supporting a new medicine. For pharmaceutical developers, this could reshape clinical strategy, reduce development timelines, and accelerate patient access to innovative therapies.

For decades, many sponsors planned development programmes around two pivotal Phase III trials, even though U.S. law has allowed approval based on a single adequate and well-controlled study with confirmatory evidence since 1997.

That supporting evidence may include mechanistic science, real-world evidence, data from related indications, animal studies, or, where appropriate, a second clinical trial.

The FDA argues that today’s drug development landscape has changed too much and regulation needs to be modernised in response.

Advances in molecular biology, biomarker science, precision medicine, and translational research mean regulators can evaluate therapies using a broader evidence framework rather than relying solely on duplicate clinical studies.

The agency also notes that many oncology studies have already been supported by one pivotal trial for approval under existing regulatory flexibility.

Rather than treating two trials as the benchmark, the FDA intends to make one robust trial the default starting point while retaining the authority to require additional studies whenever scientific uncertainty remains.

One Pivotal Trial for FDA Approval: Clinical Credibility Matters More Than Trial Numbers

One of the most important messages behind the policy is that clinical credibility cannot be measured simply by counting studies.

According to the FDA, confidence in a clinical programme depends on multiple interconnected factors, including:

• Robust randomised trial design
• Appropriate and contemporary control groups
• Clinically meaningful primary endpoints
• Strong biological plausibility
• Adequate statistical power
• Rigorous blinding and independent review
• Consistency between mechanistic and clinical evidence

• High-quality statistical analysis plans

  Image

  

A poorly designed programme does not become more reliable simply because it includes two studies.

Conversely, one exceptionally designed trial, supported by compelling clinical data, may provide stronger evidence of effectiveness than multiple weaker investigations.

This represents a subtle but important strategic shift. Sponsors may increasingly devote resources to designing one highly informative pivotal trial instead of dividing investment across multiple confirmatory studies.

Faster Development Could Improve Pharmaceutical Innovation

The potential impact of this change to one pivotal trial for FDA approval will be substantial.

The FDA estimates that a single pivotal study can cost between US$30 million and US$150 million while adding years to development timelines.

Reducing unnecessary duplication could lower development costs, improve capital efficiency, and enable promising medicines to reach patients sooner.

Potential advantages include:

• Shorter development programmes
• Lower clinical trial costs
• Faster regulatory submissions
• Improved investment efficiency
• Earlier patient access to innovative therapies

For emerging biotechnology companies, reducing the number of pivotal studies may also improve financing prospects by lowering capital requirements before commercialisation.

Read Maximise Pharma Innovation With Quality-by-Design

Maximise Pharma Innovation With Quality-by-Design

Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.

The New FDA Regulatory Standard Is Not One Size Fits All

The FDA is equally clear that one pivotal trial for approval will not become appropriate for every medicine.

Additional studies may still be required when:

• Mechanisms of action remain uncertain
• Surrogate endpoints provide limited confidence
• Clinical outcomes fluctuate substantially
• Trial limitations reduce confidence
• Biological evidence remains incomplete

In other words, flexibility does not replace clinical judgement. Instead, regulators intend to evaluate each programme according to its overall evidentiary strength rather than applying a fixed procedural requirement.

This places greater responsibility on sponsors during protocol development.

Trial design, endpoint selection, statistical methodology, and regulatory engagement may become even more important because the pivotal study carries greater weight throughout the review process.

A New Era for Clinical Development Strategy and Drug Approvals

The FDA proposal for one study for regulatory market approval has already generated discussion across the pharmaceutical sector.

Supporters argue that it reflects advances in modern biomedical science and could encourage innovation without compromising regulatory standards. Others have questioned whether more empirical evidence should be presented to demonstrate that one well-designed trial consistently provides sufficient certainty across therapeutic areas.

Regardless of where the debate settles, sponsors should not interpret the policy as permission to do less in their clinical programmes.

Instead, sponsors should expect regulators to scrutinise pivotal studies even more closely. Protocol quality, endpoint selection, statistical rigour, and confirmatory evidence will become central determinants of regulatory success.

The future of FDA approval may depend less on conducting more trials and more on designing better ones.

At Pharmatica, we analyse the regulatory changes, clinical development strategies, and emerging technologies shaping the future of pharmaceutical innovation. Our independent Insights help life sciences leaders understand how evolving evidence standards influence drug development, regulatory planning, and commercial strategy.

Pharmatica: Insight. Connection. Impact.